This is the 2022 MM+M Agency 100 honoree’s third medical communications acquisition in two years as well as the second featuring a “hyperfocused” specialty.
Verastem Oncology says let’s talk about low-grade serous ovarian cancer
While LGSOC is the fourth-most common type of ovarian cancer, it is difficult to detect, disproportionately affects younger people and has an average survival prognosis of nine years.
Pfizer shifts focus to oncology with $43B Seagen acquisition
The deferral of R&D relates to the suspension of all preclinical research, including drug discovery projects focused on identifying inhibitors of DNA damage repair.